Kopran Limited
KOPRAN.BO
Bombay Stock Exchange182.00
INR
-7.60
- -
Kopran Limited
KOPRAN.BO
(Bombay Stock Exchange)
Recent
price
182.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Kopran Limited Kopran Limited manufactures and markets active pharmaceutical ingredients and finished dosage forms, with its subsidiary Kopran Research Laboratories Limited focusing on APIs. The company offers a diverse portfolio of products including sterile cephalosporins, carbapenems such as Imipenem and Ertapenem, macrolides like Erythromycin, Clarithromycin, Azithromycin and Roxithromycin, penicillins including Amoxycillin range, cardiovascular drugs such as Atenolol, Amlodipine Besylate, Metoprolol Succinate and Tartrate, Rosuvastatin calcium, Montelukast sodium, antibacterials, anticonvulsants like Pregabalin and Lacosamide, anti-diabetics including Canagliflozin, anti-allergics, gastroenterology, pain management, anthelmintics, antiprotozoals, oncology, respiratory and central nervous system therapeutics; finished dosage forms encompass penicillin and non-penicillin based oral solid dosages, tablets, capsules, liquids, injectables and dry powder forms; APIs feature Penicillin, Rifampicin, intermediates and herbal nutraceutical products, all produced at facilities in Mahad, Khopoli and the newly acquired and upgraded site at Panoli, Gujarat. Kopran Limited operates primarily in export markets spanning over 60 countries across Africa including South Africa, Ethiopia, Tanzania, Uganda, Kenya, Zimbabwe, Latin America, Southeast Asia, the Middle East such as Oman, Iraq, Yemen, the United States, the European Union, China, Australia, CIS region and the United Kingdom, holding accreditations like US FDA, EU GMP, WHO GMP, MHRA UK, SAPHRA South Africa, Health Canada, EU GMP Malta and others for both APIs and formulations. Founded in 1958 and headquartered at Parijat House, 1076 Dr. E. Moses Road, Mumbai, India, the company pursues vertical integration by developing API intermediates, enhancing supply chain resilience through supplier diversification and in-house production to reduce reliance on China, and investing in R&D for niche high-value molecules. Recent developments include the commercialization of Montelukast sodium and Rosuvastatin calcium in FY24 with a pipeline targeting Ertapenem sodium, Edoxaban tosylate, Canagliflozin hemihydrate, Lacosamide and non-sterile Imipenem for FY25; operational enhancements via automation of formulation packing lines, yield improvements and cost optimization; capacity expansion with the Panoli API plant expected to commence commercial production by end Q3 FY25 following environmental clearance; over 549 product approvals in 46 countries and new certifications; reaffirmation of the merger scheme with promoter group entity Kopran Laboratories Limited in August 2025 as approved in March 2025 under a scheme of amalgamation by absorption with unchanged swap ratio supported by updated valuation from Ernst & Young, fairness opinion from Saffron Capital Advisors and auditor certificate; and robust FY24 financial performance with consolidated revenue of Rs 61,459 lakhs up 11.5% YoY, EBITDA up 43.7% to Rs 7,441 lakhs, PAT up 87.1% to Rs 5,096 lakhs reflecting improved margins and return ratios.